Biogen Inc.
BIIB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,455 | $2,646 | $2,431 | $2,455 |
| % Growth | -7.2% | 8.8% | -1% | – |
| Cost of Goods Sold | $877 | $946 | $578 | $584 |
| Gross Profit | $1,578 | $1,699 | $1,853 | $1,871 |
| % Margin | 64.3% | 64.2% | 76.2% | 76.2% |
| R&D Expenses | $370 | $530 | $546 | $684 |
| G&A Expenses | $0 | $0 | $0 | $612 |
| SG&A Expenses | $595 | $581 | $575 | $679 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $67 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $964 | $1,111 | $1,121 | $1,362 |
| Operating Income | $614 | $588 | $733 | $509 |
| % Margin | 25% | 22.2% | 30.1% | 20.7% |
| Other Income/Exp. Net | -$57 | $156 | -$421 | -$218 |
| Pre-Tax Income | $557 | $744 | $311 | $292 |
| Tax Expense | $91 | $109 | $71 | $25 |
| Net Income | $467 | $635 | $241 | $267 |
| % Margin | 19% | 24% | 9.9% | 10.9% |
| EPS | 3.18 | 4.35 | 1.65 | 1.83 |
| % Growth | -26.9% | 163.6% | -9.8% | – |
| EPS Diluted | 3.17 | 4.35 | 1.64 | 1.83 |
| Weighted Avg Shares Out | 147 | 146 | 146 | 146 |
| Weighted Avg Shares Out Dil | 147 | 146 | 146 | 146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $32 | $24 | $19 |
| Interest Expense | $67 | $73 | $60 | $60 |
| Depreciation & Amortization | $202 | $194 | $183 | $184 |
| EBITDA | $827 | $1,110 | $865 | $692 |
| % Margin | 33.7% | 42% | 35.6% | 28.2% |